BioArctic AB (publ) (BRCTF)
| Market Cap | 2.84B +40.2% |
| Revenue (ttm) | 216.89M +676.8% |
| Net Income | 110.91M |
| EPS | 1.25 |
| Shares Out | n/a |
| PE Ratio | 25.64 |
| Forward PE | 118.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108 |
| Average Volume | 426 |
| Open | 33.02 |
| Previous Close | 38.06 |
| Day's Range | 33.02 - 33.02 |
| 52-Week Range | 15.49 - 40.00 |
| Beta | -0.91 |
| RSI | 51.51 |
| Earnings Date | Feb 18, 2026 |
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]
News
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to particip...
BioArctic AB (BRCTF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Partnerships ...
BioArctic AB (BRCTF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Partnerships Propel Future Prospects
Q4 2025 BioArctic AB Earnings Call Transcript
Q4 2025 BioArctic AB Earnings Call Transcript
BioArctic Interim Report for the period October - December 2025
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai...
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
STOCKHOLM, Feb. 11, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2025 on Wednesday, February 18, 2026, at...
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early ...
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjun...
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM , Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innova...
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
STOCKHOLM , Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) a...
New data on lecanemab to be presented at CTAD conference
STOCKHOLM , Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's ...
Leqembi® approved for IV maintenance treatment in the United Kingdom
STOCKHOLM , Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenou...
Interim Report for the period July - September 2025: BioArctic
STOCKHOLM , Nov. 13, 2025 /PRNewswire/ -- Broadening our portfolio with new projects and partnerships Events during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress fo...
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
STOCKHOLM , Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:...
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
STOCKHOLM , Oct. 30, 2025 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction wit...
Health Canada Grants Authorization for Leqembi® (lecanemab)
STOCKHOLM , Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) fo...
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM , Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (gener...
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
STOCKHOLM , Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is n...
Leqembi® approved for IV maintenance treatment in China
STOCKHOLM , Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intraveno...
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM , Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi...
BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
STOCKHOLM , Sept. 9, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) CEO, Gunilla Osswald, has been awarded the title Alumnus of the Year ...
BioArctic's founders intend to divest minor part of their shareholding
STOCKHOLM , Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, in...
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
STOCKHOLM , Sept. 2, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics Lic...
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease
STOCKHOLM , Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License ...
BioArctic: Interim Report for the period April - June 2025
Increasing Leqembi® royalties and new partnership with Novartis STOCKHOLM , Aug. 28, 2025 /PRNewswire/ -- Events during the second quarter 2025 The European Commission granted Marketing Authorisation...
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
STOCKHOLM , Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis ...